Ondine Biomedical Inc. Stock

Equities

OBI

CA68234M2058

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. 11:35:05 2024-05-10 am EDT 5-day change 1st Jan Change
7 GBX 0.00% Intraday chart for Ondine Biomedical Inc. +6.06% -20.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2023 * 1.18M 865K Sales 2024 * 2.6M 1.9M Capitalization 27.14M 19.84M
Net income 2023 * -15M -10.97M Net income 2024 * -18M -13.16M EV / Sales 2023 * 22 x
Net cash position 2023 * 1.1M 804K Net cash position 2024 * 3.8M 2.78M EV / Sales 2024 * 8.98 x
P/E ratio 2023 *
-1.49 x
P/E ratio 2024 *
-2.41 x
Employees 18
Yield 2023 *
-
Yield 2024 *
-
Free-Float 22.43%
More Fundamentals * Assessed data
Dynamic Chart
1 week+6.06%
Current month+30.23%
1 month-6.67%
3 months-31.71%
6 months-34.58%
Current year-20.00%
More quotes
1 week
6.00
Extreme 6
7.89
1 month
5.00
Extreme 5
8.00
Current year
5.00
Extreme 5
11.40
1 year
5.00
Extreme 5
18.45
3 years
5.00
Extreme 5
60.00
5 years
5.00
Extreme 5
60.00
10 years
5.00
Extreme 5
60.00
More quotes
Managers TitleAgeSince
Founder 62 96-09-08
President 64 04-02-29
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 58 21-12-06
Founder 62 96-09-08
President 64 04-02-29
More insiders
Date Price Change Volume
24-05-10 7 0.00% 91,231
24-05-09 7 0.00% 698,607
24-05-08 7 0.00% 4,781,295
24-05-07 7 +6.06% 1,509,456
24-05-03 6.6 +28.78% 1,172,667

Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT

More quotes
Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.07 GBP
Average target price
0.55 GBP
Spread / Average Target
+685.71%
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW